Coordinated Activation of C-Src and FOXM1 Drives Tumor Cell Proliferation and Breast Cancer Progression
Overview
Authors
Affiliations
Activation of the tyrosine kinase c-Src promotes breast cancer progression and poor outcomes, yet the underlying mechanisms are incompletely understood. Here, we have shown that deletion of c-Src in a genetically engineered model mimicking the luminal B molecular subtype of breast cancer abrogated the activity of forkhead box M1 (FOXM1), a master transcriptional regulator of the cell cycle. We determined that c-Src phosphorylated FOXM1 on 2 tyrosine residues to stimulate its nuclear localization and target gene expression. These included key regulators of G2/M cell-cycle progression as well as c-Src itself, forming a positive feedback loop that drove proliferation in genetically engineered and patient-derived models of luminal B-like breast cancer. Using genetic approaches and small molecules that destabilize the FOXM1 protein, we found that targeting this mechanism induced G2/M cell-cycle arrest and apoptosis, blocked tumor progression, and impaired metastasis. We identified a positive correlation between FOXM1 and c-Src expression in human breast cancer and show that the expression of FOXM1 target genes predicts poor outcomes and associates with the luminal B subtype, which responds poorly to currently approved therapies. These findings revealed a regulatory network centered on c-Src and FOXM1 that is a targetable vulnerability in aggressive luminal breast cancers.
The Role of the Fox Gene in Breast Cancer Progression.
Pei S, Zhang D, Li Z, Liu J, Li Z, Chen J Int J Mol Sci. 2025; 26(4).
PMID: 40003882 PMC: 11855465. DOI: 10.3390/ijms26041415.
Xu C, Zhang S, Lv J, Cao Y, Chen Y, Sun H Transl Oncol. 2025; 53:102312.
PMID: 39904282 PMC: 11847097. DOI: 10.1016/j.tranon.2025.102312.
FOXM1-Driven CKS1B Upregulation Promotes Pancreatic Cancer Progression and Therapeutic Resistance.
Zhang L, Wei F, Sun Q, Huang X, Zou Q, Jiang M Int J Biol Sci. 2025; 21(3):1047-1064.
PMID: 39897042 PMC: 11781179. DOI: 10.7150/ijbs.105289.
Zhong X, Wang S, Yang X, Yang X, Zhou L Transl Androl Urol. 2024; 13(7):1145-1163.
PMID: 39100843 PMC: 11291409. DOI: 10.21037/tau-23-682.
Piemonte K, Ingles N, Weber-Bonk K, Valentine M, Majmudar P, Singh S Cancer Res. 2024; 84(21):3556-3573.
PMID: 39037997 PMC: 11534525. DOI: 10.1158/0008-5472.CAN-23-2558.